The following is a transcript of the episode
Zinc modulates glutamine metabolism in T Cells
J Nutr 136 : 1652S1659S Te Braake FW, Schierbeek H, Vermes A, Huijmans JG, van Goudoever JB 2009 High-dose cysteine administration does not increase synthesis of the antioxidant glutathione preterm infants
N l mt loi thuc quan trng iu tr bnh tiu ng loi 2 v bo ph
Who This Cluster Is For People seeking long-term metabolic stability , not temporary appetite suppression Individuals using GLP-1 medications who want durable outcomes Anyone struggling with cravings, stress eating, or appetite swings Those with gut issues, inflammation, fatigue, or metabolic slowdown Readers looking for science-driven, microbiome-based insight How to Navigate This Cluster Start with Blog 1 understand GLP-1 biology Continue with Blogs 24 learn how diet, microbes, stress, and rhythms interact Finish with Blog 5 integrate everything into a complete metabolic blueprint Revisit as needed each article stands alone Why GLP-1 Outcomes Improve When the Microbiome Is Repaired GLP-1 medications suppress appetite, but they do not correct: dysbiosis impaired SCFA production circadian disruption gut-barrier inflammation stress-driven appetite loops When microbiome function is restored, GLP-1 sensitivity improves , SCFA pathways activate, cravings stabilize, and metabolic flexibility returns
Hepaglide is developed and manufactured under strict international quality controls by Alkem Laboratories Ltd, a globally trusted pharmaceutical leader
